The rising prevalence of osteoarthritis (OA) in the general population has necessitated the
development of novel treatment options. It is critical to recognize the joint as a separate …

Opinion statement Osteoarthritis (OA) is not merely a degenerative disease but a disease of
the whole joint. The aims of OA treatment are to alleviate pain and to improve function. The …

The success of disease-modifying osteoarthritis drug (DMOAD) development is still elusive.
While there have been successes in preclinical and early clinical studies, phase 3 clinical …

Osteoarthritis (OA) is an age-related condition and the leading cause of pain, disability and
shortening of adult working life in the UK. The incidence of OA increases with age, with 25 …

ABSTRACT A disease-modifying osteoarthritis drug (DMOAD) is a drug that modifies the
underlying OA pathophysiology and potentially inhibits the structural damage to prevent or …

Despite its growing prevalence, osteoarthritis (OA) remains a poorly understood disease,
and recent doubts about the safety of several commonly prescribed OA medications have …

OA is a common age-related condition of synovial joints that is characterized pathologically
by localized areas of loss of articular cartilage associated with overgrowth of bone at the …

With a frustrating lack of progress in the development of treatments for osteoarthritis, EULAR
has released recommendations to reorient research into this disease. These …

Osteoarthritis (OA) is the most common specific joint disease in humans and the largest
cause of chronic disability in the elderly (1–5). Historically, treatment of OA has been …

Osteoarthritis (OA) is a slowly, progressive, ultimately degenerative disorder of movable
joints, mainly characterized by joint pain and functional limitation and affecting all joint …